ArticleAnnals of hematology2026

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.

Jing Ruan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.